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Pylephlebitis  is an uncommon  complication  of  uncontrolled  intra-abdominal  infection  that  is  associated
with  high  morbidity  and  mortality.  We  present  our experience  with  a unique  case  of cecal  divertic-
ulitis  and  septic  thrombophlebitis  of the superior  mesenteric  vein  that  was  promptly  diagnosed  withccepted 9 June 2016
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high-resolution  imaging  and  blood  cultures.  Antibiotic  and  anticoagulation  therapy  was  instituted  on
conﬁrming  the  diagnosis  with  magnetic  resonance  imaging  (MRI)  to control  the  infection  and  prevent
propagation  of  the  thrombus.  Our  case  report  raises  awareness  about  a rare  and  potentially  fatal  condition
and  provides  appropriate  imaging  supplementation  to aid in  timely  diagnosis.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCuperior mesenteric vein thrombosis access  article  under  t
. Introduction
Pylephlebitis or suppurative thrombosis of the portal mesen-
eric venous system is a rare complication of intra-abdominal
nﬂammatory processes such as diverticulitis, appendicitis, pan-
reatitis and inﬂammatory bowel disease [1–5]. Clinical symptoms
re non-speciﬁc and include fevers, abdominal pain and nausea
6]. Diagnosis requires imaging ﬁndings of thrombosis in the portal
enous system on computed tomography (CT) or MRI  in conjunc-
ion with clinical symptoms [7,8]. If untreated, the condition is
otentially fatal. Current treatment regimens are largely based on
necdotal experience with this condition. While antibiotic ther-
py is a universal recommendation, the role of anticoagulation is
ontroversial with most studies failing to demonstrate a statisti-
ally signiﬁcant beneﬁt [9–11]. We  present a case of suppurative
hrombophlebitis of the superior mesenteric vein secondary to
ecal diverticulitis. We  have highlighted pertinent imaging ﬁndings
nd modalities to treat this condition.
. Presentation of caseA 57 year-old African-American male with a past medical his-
ory of diabetes, hypertension, benign prostatic hyperplasia and
sthma presented to the emergency room with three days of epi-
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gastric pain, nausea, vomiting and an inability to tolerate solid
food. He reported regular bowel movements and was  passing ﬂa-
tus on presentation. He had no prior abdominal surgeries and no
family history of crohn’s disease, ulcerative colitis or gastrointesti-
nal malignancies. His medications included terazosin, lisinopril,
amlodipine and metformin. He reported smoking half a pack of
cigarettes/day for the last 40 years and using heroin intermittently
over the last few months.
On Physical exam, he was morbidly obese with a BMI  of 36.32.
He was febrile to 38.4, tachycardic to 102/minute and saturat-
ing within normal limits on room air. His abdomen was soft,
non-distended without tenderness, guarding or rebound. He had
normoactive bowel sounds and his rectal exam was unremarkable
with hemoccult negative stool in the rectal vault.
There were no acute changes in electrocardiography or tro-
ponin level. Hematology showed leukocytosis with neutophilia and
bandemia. His basic metabolic panel was remarkable for hypona-
tremia, hypochloremia and hyperglycemia. The most concerning
laboratory ﬁnding was  his elevated total bilirubin of 7.2 mg/dl with
a direct bilirubin of 5.1 mg/dl. His alkaline phosphatase, serum
transaminases and lipase were within normal limits. His procalci-
tonin level was elevated to 58.2 ng/ml (normal < 0.1 ng/ml). Blood
cultures were collected and sent for microbiological analysis.
Abdominal contrast-enhanced CT revealed scattered colonic
diverticulosis with abnormal stranding of the mesenteric vessels in
the posterior midline, concerning for mesenteric thrombophlebitis.
There was associated thickening of the distal ileum and cecum
along the inferior boundary of the process, likely due to cecal diver-
ticulitis (Fig. 1A). In addition, there was a questionable thrombus
at the conﬂuence of the superior mesenteric vein and portal vein
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. (A) CT abdomen and pelvis with oral and intravenous contrast. Abnormal fat
stranding of the mesentery (long arrow) and thickening of the terminal ileum (short
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demonstrated in conjunction with culture positive ﬂuid from therrow). (B) Suspected thrombus at the conﬂuence of the superior mesenteric and
ortal veins (arrow).
Fig. 1B). The biliary system was unremarkable on CT. An MRI  was
ecommended for further evaluation.
The patient was admitted and bowel rest along with aggressive
uid resuscitation and broad-spectrum antibiotics were initiated.
RI  conﬁrmed the presence of a thrombus in the distal superior
esenteric vein just below the conﬂuence of the portal vein (Fig. 2).
n conjunction with the CT ﬁndings earlier, this was thought to be
ue to the propagation of mesenteric thrombophlebitis, secondary
o cecal diverticulitis. An unfractionated heparin drip was initiated.
Over the next two days, he was afebrile, his leukocyte count
rended downward and his symptoms improved signiﬁcantly. His
ilirubin continued to trend downward, ultimately reaching a
evel of 2.6. A hepatitis panel was non reactive. His procalcitonin
ecreased from an original 58–14.5 ng/ml.
His blood cultures conﬁrmed the presence of beta lactamase
roducing Bacteroides fragilis, sensitive to ampicillin-sulbactam
nd his antibiotic regimen was accordingly modiﬁed. He was
tarted on a liquid diet, which was gradually advanced to solid foods
s tolerated. He was switched to oral amoxicillin-clavulanate andFig. 2. T1- weighted coronal magnetic resonance imaging of the abdomen showing
thrombus within the distal superior mesenteric vein just below the conﬂuence of
the portal vein (arrow).
bridged to coumadin. His anticoagulation regimen was later mod-
iﬁed to rivaroxaban. He was discharged home after eight days on
an additional 10 days of amoxicillin-clavulanate and 6 months of
rivaroxaban with close follow up with his hematologist.
3. Discussion
The above case illustrates the vague clinical presentation of
pylephlebitis in conjunction with an intra-abdominal inﬂamma-
tory process. The elevated bilirubin raised clinical suspicion for
portal pyemia and further workup was tailored toward detecting
the disease. Although CT ﬁndings were equivocal, testing was  pur-
sued with MRI. Antibiotic and anticoagulation therapy was initiated
immediately on diagnosis.
Our patient presented with gastrointestinal symptoms, fevers
and leukocytosis with a left shift, suggestive of an intra-abdominal
infection. Belhassen-García et al. in their review of 7796 patients
from 1999 to 2006 noted that 13 (0.6%) patients with intra-
abdominal infections developed pylephlebitis [3]. The incidence
of this condition has been estimated at about 2.7 per 100,000
patient years with diverticulitis being the most common incit-
ing event [1–7]. Other common pathologies include appendicitis,
pancreatitis and inﬂammatory bowel disease [4–7]. Smoking and
obesity, as in the case presented above were likely contributing
factors to the development of superior mesenteric venous throm-
bus. A high index of suspicion must be maintained in patients with
uncontrolled abdominal infections and risk factors for hyperco-
agulability [8]. Our ultimate diagnosis of pylephlebitis was based
on MRI  ﬁndings of superior mesenteric venous thrombosis and
the growth of Bacteroides fragilis from peripheral blood cultures.
Pylephlebitis is deﬁnitively diagnosed when venous thrombosis isportal venous system. However, portal vein aspiration is seldom
performed, given its invasiveness. A review of 95 cases of pyle-
phlebitis associated with intra-abdominal infection by Choudhry
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t al. deﬁned this condition as portal mesenteric venous thrombosis
ith or without bacteremia within 30 days of an intra-abdominal
nﬂammatory process [9]. The review included patients with diver-
iculitis, pancreatitis, inﬂammatory bowel disease and appendicitis
ho consequentially developed suppurative thrombophlebitis of
he right portal (31 patients), left portal (23 patients), main portal
30 patients), superior mesenteric (29 patients), inferior mesen-
eric (8 patients) or splenic veins (17 patients). There were patients
ho had two  or more sites of involvement in each category. The
ight and the main portal veins were the most common sites of
nvolvement.
The imaging ﬁndings in the case above were suggestive of supe-
ior mesenteric venous thrombosis on CT (Fig. 1B). The portal
enous phase has the highest diagnostic value for pylephlebitis and
an detect sequelae such as hepatic abscesses and intestinal infarc-
ion. Characteristic imaging ﬁndings on CT include a well-deﬁned
ntraluminal-ﬁlling defect with central low density surrounded by
im-enhancing venous walls [12]. MRI  demonstrated a distinctive
entral thrombus in the distal superior mesenteric vein just below
he conﬂuence of the portal vein (Fig. 1B). Fresh thrombi less than
ve weeks old are usually hyperintense on T1 and T2 weighted
equences compared to the liver parenchyma and the surround-
ng muscle tissue [12]. Other useful imaging modalities include
uplex ultrasound, which typically demonstrates a ﬂow defect with
roximal dilation or absent compressibility of the affected vein
12]. Baril et al. and Plemmons et al. recommended that blood
ultures should be drawn in cases of suspected pylephlebitis; how-
ver, the incidence of bacteremia varies widely between 23–88%
10,11]. Bacteroides fragilis is the most commonly isolated organ-
sm in monomicrobial infections of the portal mesenteric system
6]. Bacteroides is known to activate the coagulation cascade via
he production of anticardiolipin antibodies, which break down
eparin. The capsular components of the organism accelerate
brin cross-linking and thereby, promote thrombosis. Other fre-
uent isolates include Streptococcus viridans, Escherichia coli and
olymicrobial sources.
Our case reported an unusual site of venous thrombosis in the
istal superior mesenteric vein. Baril et al. reported the main portal
enous system is a far more common site of involvement compared
o the mesenteric veins [10].
Once a diagnosis was  established initial broad-spectrum antibi-
tic therapy was instituted, which was later modiﬁed based on
lood culture results. A dramatic improvement in clinical and
aboratory parameters was achieved. The largest institutional
etrospective review by Choudhry et al. recommended empiric
ntibiotic therapy in 86 patients with pylephlebitis [9]. Plemmons
t al. have recommended intravenous antibiotic therapy until a
igniﬁcant response occurs followed by oral antibiotic therapy. A
otal duration of 4 weeks of antibiotic therapy was  recommended
y this study [11]. There are currently no societal or organization
uidelines on the duration of antibiotic therapy given the rarity of
he disease. In the above case, a total of 18 days of antibiotic ther-
py was administered based on the recommendations of a team
f infectious disease specialists. Delays in management of pyle-
hlebitis have been associated with mortality rates as high as 25%
9]. Early broad-spectrum antibiotic therapy, even in the absence of
ositive bacteremia has proved to decrease the incidence of poten-
ially fatal conditions such as bowel ischemia and hepatic abscesses
9].
In the case presented above, there were no contra-indications
o the use of long-term anticoagulation and the decision was
ade to proceed with therapeutic anticoagulation. Baril et al.tudied 44 patients with septic thrombophlebitis of the portal
ein and reported 5 deaths in the group of 32 patients who did
ot receive anticoagulation vs. none in the 12 that did receive
nticoagulation[10]. Duffy et al. demonstrated recanalization of thePEN  ACCESS
gery Case Reports 25 (2016) 71–74 73
portal vein after anticoagulation in a patient with pylephlebitis sec-
ondary to diverticulitis [13]. Kanellopoulou et al. examined 100
cases of pylephlebitis, all of whom received antibiotic therapy
and 35 of who received anticoagulation in addition to antibiotic
therapy. Patients who received anticoagulation had a favorable out-
come compared to those who  received antibiotics alone (complete
recanalization 25.7% vs. 14.8% (p > 0.05), no recanalization 5.7% vs.
22.2% (p < 0.05) and death 5.7% vs. 22.2% (p < 0.01)) [6]. On the other
hand, a retrospective review by Choudhry et. al which included 95
patients with portal, mesenteric and splenic pylephlebitis showed
similar mortality rates when antibiotics were used with or with-
out anticoagulation (10 vs. 20%, p = 0.265) [11]. Given our limited
experience with the disease, our recommendation is that anticoag-
ulation therapy should be individualized, carefully weighing the
risks with the beneﬁts. In the absence of an underlying coagu-
lopathy, Allaix et al. recommended 3–6 months of anticoagulation
treatment [14]. As yet, the end point of anticoagulation has not been
well deﬁned [14,15].
Our study did present certain limitations in terms of diagnos-
tic workup and follow up. Although cecal diverticulitis was  our
primary diagnosis on imaging, alternative considerations such as
crohn’s disease and septic thromboemboli from infective endo-
carditis were not pursued. Furthermore, our patient did not receive
a follow up MRI  after completion of antibiotic and anticoagulation
therapy.
4. Conclusion
Our case report summarizes the clinical features, imaging and
therapeutic modalities of an unusual entity. To date, ours is the
only case report on pylephlebitis secondary to cecal diverticulitis
that illustrates the utility of MRI  when CT ﬁndings are equivocal
[4,16]. Our results are a valuable addition to surgical literature in
terms of guiding clinical judgment and improving outcomes.
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